CStone Pharmaceuticals reports clinical data for CS2009 at ESMO 2026
CStone Pharmaceuticals has presented phase 1/2 data for its trispecific antibody candidate, CS2009, indicating tumor reduction across diverse solid tumor types in a study of over 300 patients.
At the 2026 European Society for Medical Oncology (ESMO) congress, CStone Pharmaceuticals released clinical trial results for CS2009, a trispecific antibody designed to target PD-1, VEGF, and CTLA-4 pathways simultaneously. The data, derived from a cohort of 300 patients, aims to demonstrate the drug's activity in treating solid tumors.
The study focused on the drug's safety profile and its efficacy in patients who have not responded to conventional checkpoint inhibitors. By targeting three pathways, CStone aims to address the issue of treatment resistance in oncology, though long-term durability of these responses remains a primary metric for future clinical assessment.
CS2009 remains in development as the company attempts to differentiate its asset in a crowded immuno-oncology market. CStone leadership noted that the trial results provide a foundation for further late-stage testing. The company plans to initiate additional trials to refine dosing strategies and identify specific patient subgroups that benefit most from this multi-pathway approach.